iifl-logo

Alivus Life Sciences Ltd Management Discussions

Add as a Preferred Source on Google
₹1,444.7
(-0.21%)
Nov 18, 2026|03:54:58 PM

Alivus Life Sciences Ltd Share Price Management Discussions

Macro Economy

Global Economy

The global economy in 2026 is trending a tightrope of resilience and rising downside risks, shaped significantly by recent geopolitical developments and evolving macroeconomic conditions. According to the IMF, global growth is now projected at approximately 3.1%, a downward revision from earlier expectations of around 3.3%, an impact of escalating geopolitical concerns, particularly the ongoing Middle East conflict and tighter financial conditions. Growth remains below long-term averages, indicating a subdued but stable expansion phase.

The focal point in 2026 is the renewed inflationary pressure driven by supply-side shocks, especially in the energy and commodity markets. Disruption of critical trade routes and elevated oil prices have pushed global inflation projections higher, with estimates rising to around 4.4% for the year. In response, central banks are likely to remain cautious on monetary easing, balancing inflation risks with the need to support growth. Under adverse scenarios, the risk of stagflation, characterised by weak growth and persistent inflation, has increased.

Fiscal pressures are also becoming more pronounced. The IMF estimates that global public debt, already elevated at approximately 94% of GDP in 2025, is on a rising trajectory and could approach 100% by the end of the decade. Higher interest rates and increased government spending in response to economic shocks are placing additional pressure on fiscal balances, particularly in emerging and developing economies. Policymakers are therefore expected to focus on targeted fiscal interventions and rebuild buffers to ensure medium-term sustainability.

Divergence across regions remains pronounced. Advanced economies are seeing moderate growth, supported by resilient labour markets and technological investment, particularly in artificial intelligence. Meanwhile, emerging markets face more acute challenges due to exposure to commodity price volatility, capital flow shifts, and currency pressures. Growth in emerging economies has been revised down to approximately 3.9% for 2026, with energy-importing countries disproportionately affected.

Outlook

While the global economy in 2026 continues to show improvements in pockets, the risks clearly remain tilted to the downside. Geopolitical tensions, elevated debt levels, and persistent inflationary pressures are likely to weigh on growth. At the same time, structural drivers such as technological advancement and selective fiscal support offer potential upside. The outlook therefore remains contingent on the evolution of geopolitical developments, energy markets, and the effectiveness of policy responses in maintaining macroeconomic stability.

(Chart: IMF REFERENCE GLOBAL GROWTH FORECAST: 3.4% in 2025, 3.1% in 2026, 3.2% in 2027) (Chart: World Economic Outlook April 2026 GROWTH PROJECTIONS BY REGION - World: 3.4 (2025), 3.1 (2026), 3.2 (2027); United States: 2.1 (2025), 2.3 (2026), 2.1 (2027); Euro Area: 1.4 (2025), 1.1 (2026), 1.2 (2027); Middle East and Central Asia: 3.6 (2025), 1.9 (2026), 4.3 (2027); Emerging and Developing Asia: 5.5 (2025), 4.9 (2026), 4.8 (2027); Sub-Saharan Africa: 4.5 (2025), 4.3 (2026), 4.4 (2027); Latin America and The Caribbean: 2.4 (2025), 2.3 (2026), 2.7 (2027)) Source: IMF, World Economic Outlook, April 2026. Note: Order of bars for each group indicates (left to right): 2025 estimates, 2026 projections, and 2027 projections. Source: IMF WEO, Apr 2026 & EY

Indias economic outlook for FY2026 indicates a moderation in growth following a strong FY2025, while remaining resilient relative to global peers. The Asian Development Bank, projects GDP growth at 6.9% in FY2026, easing from 7.6% in FY2025, before recovering to 7.3% in FY2027. The moderation reflects heightened global uncertainty, including geopolitical tensions in the Middle East, elevated energy prices, and volatile trade and financial conditions, which are expected to impact exports, inflation, and capital flows in the near term.

Domestic demand is expected to remain the key growth driver. Private consumption should stay steady, supported by rising incomes, stable rural demand, and relatively accommodative monetary conditions, although inflationary pressures and fading fiscal support may temper its pace. Investment activity continues to support growth, with central government capital expenditure budgeted to increase by 11.5% in FY2026. Improved corporate and banking sector balance sheets, alongs old corporate and enhanced logistics, are expected to sustain private investment momentum.

Macroeconomic indicators suggest manageable but evolving pressures. Inflation is projected to rise to around 4.5% in FY2026 on the back of higher food and energy prices, before easing to 4.0% in FY2027 as supply conditions improve. The current account deficit is expected to widen in the near term, driven by higher import costs, particularly crude oil, but should narrow subsequently with normalization in global energy markets and stronger export performance supported by recent trade agreements. Meanwhile, manufacturing and services sectors are likely to remain robust, supported by policy incentives, global integration, and strong demand for high-value services.

Outlook

Indias economic outlook remains positive as growth is likely to stabilize and strengthen despite near-term headwinds, supported by strong domestic fundamentals, continued public investment, and structural reforms. While near-term risks from global volatility, energy prices, and inflation persist, prudent macroeconomic management is expected to support stability and sustaining growth momentum.

(Chart: India GDP Growth Forecast: 7.1% (2024), 7.6% (2025), 6.9% (2026), 7.3% (2027))

Pharmaceutical Industry

Global Pharmaceutical Industry

The global pharmaceutical industry continues to expand, with market size projected to increase from USD 1.62 trillion in 2025 to an estimated USD 1.72 trillion in 2026, representing an annual growth rate of 5.8%. This growth is primarily driven by ageing populations, rising demand for chronic disease treatments, and robust innovation across biologics, metabolic drugs, and oncology therapies. GLP-1 therapies, in particular, have emerged as a significant growth driver, reshaping treatment paradigms in metabolic disorders. According to Morningstar DBRS, the sector remains relatively defensive, supported by stable healthcare demand and ongoing technological advances, despite policy uncertainties and geopolitical volatility.

Key trends shaping the industry include:

? Strategy M&A and Partnerships: More than 70 high-revenue drugs approaching patent expiry are expected to fuel another year of large-scale mergers, acquisitions, and biotech collaborations.

? Optimism with Caution: Following recovery from the 2025 downturn, investor sentiment is improving, but competition especially from China and regulatory unpredictability still cause tension.

? Resilient but Adaptive Organizations: Over 75% of life sciences executives remain financially optimistic yet recognise the need for local resilience and agility amid global uncertainty.

? AI and Digital Acceleration: Artificial intelligence is streamlining drug discovery, clinical trials, and commercialisation, making pipelines more efficient and shortening time-to-market.

The sector faces notable challenges like:

? Pricing and Policy Reform: Implementation of U.S. Medicare Maximum Fair Prices and global cost-control initiatives are expected to squeeze margins.

? Patent Cliffs: Loss of exclusivity for key blockbuster drugs could erode sales by up to 80% as biosimilars and generics expand.

? Inflation and Supply Chain Pressure: Persistent input cost inflation and reshoring of manufacturing may strain profitability.

? Regulatory and Geopolitical Volatility: Shifting U.S. FDA policies and global trade tensions, particularly with China, could delay launches and disrupt global operations.

Outlook

Viewed through a multi-year lens, the pharmaceutical sector emerges as more than a traditional defensive play; it is structurally aligned for sustained, innovation-led growth. Although year-to-year performance may experience volatility due to regulatory developments or policy changes, the outlook for 2026-2030 remains constructive. The period is expected to be defined by steady, resilient growth, increasing scientific output, and the sectors enduring strategic importance within global healthcare systems.

Indian Pharmaceutical Industry

Indias pharmaceutical industry in 2026 remains a global leader in affordable medicines, supported by strong manufacturing and regulatory capabilities.

The market is estimated at around USD 60 billion and is projected to reach nearly USD 80 billion by 2031, reflecting steady expansion and a shift toward innovation, complex generics, and biosimilars.

Growth is expected at 9-11% driven by domestic demand and exports. The domestic market may grow by 7-8% on the back of chronic therapies, while exports exceeding USD 30 billion continue to expand across regulated and emerging markets.

Key growth drivers will be:

? Innovation and R&D Expansion: Indian companies are moving up the value chain, with investments in biosimilars, novel drug delivery systems, and complex generics. The governments PLI (Production Linked Incentive) Scheme continues to encourage investment in high-value manufacturing and R&D infrastructure.

? Export Resilience and Diversification: With over USD 30 billion in annual exports, India will remain a global hub for generic and API production, but firms are diversifying away from the U.S. market and expanding into Africa, Latin America, and Southeast Asia to offset regulatory and pricing risks.

? Domestic Healthcare Expansion: Rising healthcare access through Ayushman Bharat, growing insurance penetration, and urban middle-class demand will boost domestic consumption, especially in chronic disease, gynaecology, and lifestyle segments.

? Biopharma and Healthcare Ecosystem Growth: Increasing collaboration between industry, academia, and startups is fuelling Indias biotech and clinical research ecosystem, positioning it as a key global partner for vaccine and biosimilar development.

? Digital and AI Integration: The industry continues to explore opportunities to leverage AI and data analytics across pharmaceutical research, development, and commercial functions. Successful adoption of these technologies could drive greater efficiency, faster innovation cycles, and improved global competitiveness for Indias pharmaceutical sector.

Outlook

Indias pharmaceutical industry will remain a fast-growing pillar of the global healthcare supply chain anchored by cost-efficient production, digital innovation, and expanding domestic demand.

While pricing regulation and compliance complexity pose challenges, the sectors adaptability, scale, and advancing R&D strength position it for sustained mid- to-high single-digit growth and rising global influence through 2026 and beyond.

Sources: Mordor Intelligence, Express Pharma, Fortune India, Atradius, Morningstar, ZS, Epicflow, Biopharma Dive & EY

Global API Industry

The global Active Pharmaceutical Ingredients (API) industry in 2026 continues to play a critical role within the broader pharmaceutical value chain, supported by sustained demand for both generic and innovative medicines. The market size is estimated at approximately USD 245-287 billion in 2026 and represents a significant share of global pharmaceutical production.

APIs remain central to drug development and manufacturing, with increasing importance driven by rising incidence of chronic diseases, expanding healthcare access in emerging markets, and growing demand for specialty therapies.

Growth in the API industry remains steady, with projected CAGR in the range of 5.5% - 7.3% over the medium term. The market is expected to expand to over USD 400 billion by the early 2030s, supported by increasing pharmaceutical consumption, patent expiries driving generics, and continued investment in research and development.

Key Trends in the Global API Industry:

? Shift toward complex and high-value APIs, including specialty molecules and biologics, driven by evolving drug pipelines and precision medicine

? Rapid growth in demand for oncology and targeted therapies, influencing API innovation and capacity expansion

? Increasing outsourcing to contract development and manufacturing organisations (CDMOs) to improve efficiency and scalability

? Supply chain diversification and onshoring strategies to reduce dependence on concentrated manufacturing regions

? Adoption of advanced manufacturing technologies, including continuous manufacturing and digitalisation

? Heightened regulatory scrutiny and compliance requirements across major markets

? Rising focus on sustainability and green chemistry practices in API production

? Strengthening role of emerging markets, particularly India and China, as key API manufacturing hubs

Global High Potency APIs (HPAPI) Market:

The global high-potency API (HPAPI) segment is witnessing faster growth compared to the overall API market, driven by increasing demand for oncology and targeted therapies. HPAPIs are essential for the development of highly selective drugs such as antibody-drug conjugates and precision medicines, which require specialised manufacturing capabilities and stringent safety standards. The expansion of biologics pipelines, coupled with rising investments in specialty therapeutics, is accelerating capacity additions in this segment. This has also led to higher barriers to entry, favouring established players with advanced containment technologies and regulatory expertise.

Global API CDMO

The global Active Pharmaceutical Ingredient (API) CDMO industry in 2026 represents a fast-growing and strategically critical segment within the broader pharmaceutical outsourcing ecosystem. API-focused CDMOs provide end-to-end services spanning process development, scale-up, and commercial manufacturing, enabling pharmaceutical and biotechnology companies to accelerate time-to-market while managing costs and complexity. The market is estimated at over USD 110-115 billion in 2025-2026, forming a significant share of the overall CDMO industry. Increasing drug complexity, rising R&D intensity, and the need for flexible manufacturing solutions are reinforcing the importance of API CDMOs as long-term strategic partners rather than transactional service providers.

The industry is witnessing strong growth momentum, with the global API CDMO market projected to expand at a CAGR of approximately 7.5%-8.0% through 2030-2033, reaching over USD 200 billion by the early 2030s. Growth is primarily driven by increasing outsourcing by pharmaceutical companies seeking cost efficiency and specialized capabilities, along with a robust pipeline of complex and high-value therapies. Demand is particularly strong in small molecules, which continue to dominate volumes, while high-potency APIs (HPAPIs) and biologics-linked APIs are growing at a faster pace due to their role in oncology and precision medicine. Additionally, Asia-Pacific is emerging as the fastest-growing region, supported by cost advantages, expanding infrastructure, and favorable policy environments.

Outlook

The global API CDMO industry presents an attractive medium-term growth opportunity over the next three to five years, supported by structural outsourcing tailwinds, rising molecule complexity, and growth in specialty and high-value pipelines. CDMOs with differentiated technology platforms, high-potency capabilities, and integrated service models are likely to emerge as relative winners despite ongoing near-term operating challenges.

Source: Grand View Research & EY

Advantage Alivus Life Sciences

Management

Alivus Life Sciences is a professionally managed company, supported by an experienced Board that guides our independent strategic direction for the future. Our management team has consistently demonstrated strong capabilities in building and integrating the business across diverse operational functions, leveraging their extensive cumulative industry experience.

In particular, they have led the process and created value through organic growth, built brand recognition and loyalty and identified new business opportunities.

This has been accomplished through a well-balanced portfolio expansion strategy, with commercialization expected over a 2-6 years horizon, while maintaining focus on:

? PORTFOLIO GROWTH with higher value molecules via expansion of platform technologies

? GEOGRAPHIC EXPANSION

? EFFECTIVE COST MANAGEMENT

? EFFICIENCY ENHANCEMENT MEASURES

? DE-RISKING THE SUPPLY CHAIN

In addition, we have a strong corporate governance system to monitor, guide and support our business and operations.

Business Overview

API Generics

At Alivus, we built a portfolio of high value, non-commoditised APIs in chronic therapeutic segments, namely, Cardiovascular (CVS) disease, Central Nervous System (CNS) disorders, Pain Management, Oncology, Diabetes and Urology for our customers worldwide.

Some of these APIs such as Amiodarone, Ezetimibe (CVS), Lithium carbonate, Oxcarbazepine (CNS), Mirabegron, Solifenacin (Urology), Atovaquone (anti-parasitic), Etoricoxib (Pain) and Dapagliflozin, Sitagliptin (Diabetes), have a significant and growing market share in major world markets.

Our API product portfolio spans multiple therapeutic areas such as CVS, CNS, Pain, Diabetes, Urology, Oncology and other therapeutic areas. A snapshot of key molecules classified by therapy areas is below:

Therapy Count of product
Anti-infective 12
CNS 27
CVS 31
Diabetes 13
Gastro 9
Oncology 20
Others 50
Pain management 7
Respiratory 7
Grand Total 176

We continue to add specialised and profitable products into our portfolio, including niche and technically complex molecules, such as Ensifentrine, Elacestrant, Finerenone, Elinazentant, Tivozanib, Vonoprazan & Isavuconazonium Sulfate.

Our total portfolio of 176 API molecules is sold in India and exported to multiple countries in Europe, North America, Latin America, Japan and the rest of the world (ROW).

We had filed 611 Drug Master Files (DMFs) and Certificates of suitability to the monographs of the European Pharmacopoeia (CEPs) across various major markets (i.e. United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia). We work with 20 of the largest generic companies globally.

176 API Molecules sold in India & exported to multiple countries 611 DMFs & CEPs filed across various major markets

CDMO

In the last 7 years, we have developed business with innovator and specialty pharmaceutical companies in the area of CDMO.

Given our capabilities in process chemistry research, manufacturing from grams to tonnes and analytical research capabilities, we have the ability to attract innovator pharmaceutical companies to partner with us for providing unique solutions tailored to their specifications.

We provide lifecycle management solutions for their mature portfolio where genericsation has happened or is impending. In our current global portfolio of 176 molecules, many molecules offer such opportunities to a complete new set of customers. In addition, we are focused on APIs for Specialty development companies as an important sub-segment of our CDMO business. We see the specialty business as a key growth opportunity and an added lever for our API market expansion, with multiple companies in the United States currently focused on developing 505(b)(2) products. The specialty business offers higher business stability (with improved margins) due to the complex nature of the products thereby leading to higher customer stickiness.

Within this segment, we offer customised support to pharmaceutical companies from making regulatory filings, providing research and technological support, to manufacturing specialty APIs. As an API provider to such customers, we have helped to create value through a blend of product customisation and regulatory strategy to allow market access.

Alivus today operates as a standalone company, generating a higher level of confidence with CDMO customers for building partnerships through technology transfer arrangements.

Our process research, analytical research and chemistry capabilities enable CDMO services for a range of multinational corporations and specialty companies.

We believe that innovators prefer to select vendors with a strong track record. Our continuous focus on quality and on the sustainability of our operations make us a serious contender to grow this business opportunity.

Evolving Our Business Strategy

Even after the world economy had multiple setbacks (COVID, energy prices, war, inflation, banking stress, etc.) with a direct impact on our industry, Alivus continues to experience robust demand for APIs across most geographies albeit, with a need for competitive prices. This scenario opens-up an opportunity for high-quality APIs with affordable pricing in a large portion of our product portfolio.

Our continuous focus on cost optimisation to become more efficient via next-generation processes, improved manufacturing, solvent recovery, lower-cost energy and an overall savings effort to do more with less has helped us to deliver growth with sustainable margins.

Although this was always one of our business mantras, we applied an even greater focus to make a difference to the customers and patients whom we eventually serve. The multiple touch points of our strategy to fuel the growth, retain the margins while creating a sustainable platform to ensure business continuity are outlined here:

? Expand the existing business

o New product launches

o Geographical expansion in order to reduce our dependence on limited geographies

o Focus on new markets becoming more regulated. This initiative drives higher value by virtue of support to the customer throughout their development and commercialisability

o Pursue 2nd source opportunities with top generic players in molecules where Alivus holds a position of cost leadership

? New growth levers

o CDMO business expansion with a plan to leverage a significant part of our existing portfolio for 505(b)(2) and lifecycle management projects

o Expand into complex API platforms e.g. Iron compounds, Oncology and HPAI

? Cross-selling

o With a large product basket, Alivus has been strategically cross-selling existing products to existing customers in other geographies thereby increasing the wallt share of the customer

? Operational Efficiencies

o Measures to reduce costs, improve efficiencies and reallocate resources to support newer initiatives in energy savings, water recycling, solvent recovery and automation.

? R&D initiatives

o Productivity improvement of existing processes through constant optimisation

o Process cycle time reduction

o Qualifying lower-cost processes for regulated markets

o Better recovery & recycling

o Backward integration of higher value KSMs (Key Starting Materials)

? Sourcing Initiatives

o Ongoing negotiations with vendors (based on market environment)

o Alternate vendor qualification

? Operations Initiatives

o Solvent recovery and recycling

o Optimisation of batch sizes

o Utilisation of new downstream equipment for filtration or drying techniques

o Yield improvement

o Automation for better efficiencies

o Green chemistry and effluent reduction

Manufacturing

We currently operate four multi-purpose manufacturing facilities located at Ankleshaw and Dahej in Gujarat and, Mohol and Kurkumbh in Maharashtra. Our combined reactor capacity stands at 1,424 KL in FY26, and we have manufactured a quantity of 888 MT in FY26. To support the increased volumetric capacities and quantum of production for upcoming FY27, we have upgraded the infrastructure of supporting departments like warehouse, effluent treatment plants, etc. and are working to improve resource optimisation and efficiency to leverage maximum outcome in FY27. In FY26 we have successfully commissioned our first continuous manufacturing plant at Ankleshaw and have commercialised one global product from the plant.

The new API facility in Chincholi Industrial Area, Solapur, will be operational in FY27 and is planned to manufacture both APIs and intermediates.

It will house several multi-purpose manufacturing blocks with mid to high volume capacity. This new facility will also provide a platform for the growth of our CDMO business and add capacity for our generic API business.

This substantial increase in capacity and capability will empower us to produce all commercial Active Pharmaceutical Ingredients (APIs), annually achieving projected gross commercial-scale manufacturing tonnage totalling to 900+ metric tons in FY27. Our facilities have been subject to 56 inspections and audits by regulators which includes the USFDA, PMDA (Japan), COFEPRIS, Health Canada, MFDS (Korea), EDQM, ANVISA (Brazil), WHO and CDSCO, conducted on a periodic basis.

Recently our Ankleshaw and Dahej facilities were inspected by the USFDA.

Capacity Expansion

? Construction work for expansion of three pharma blocks is underway at Ankleshaw Site and shall be operational by Q4FY27 (100KL).

? Two independent modules are already commissioned and operational at Dahej Site at present.

? New R&D centre underway with capabilities for API, CDMO businesses and new API platforms

? Installation of additional columns are planned at both Ankleshaw and Dahej for solvent recovery enhancement.

? 160 KL new capacity planned in Dahej in Q3FY27.

? Product validation in a new facility for manufacturing through flow chemistry at Ankleshaw site in FY26.

? New ETP in Ankleshaw was completed in FY26.

? Construction work is ongoing in Solapur for 465 KL in phase 1 and 2.

Quality Focus

We have built a Quality Management Systems (QMS) to build quality into the manufacturing and business processes which are aligned with the organisations focus on quality by design (QbD).

To further strengthen the QMS compliance,

\uf0b7 Raw material Warehouse Barcode label system implemented \uf0b7 Data logging system installed for the manufacturing equipment used to manufacture final API \uf0b7 New technology - Flow chemistry system i.e Tubular reactor & Agitated thin film evaporator, Homogenizer, Nanofiltration system implemented at site. April-2025 to Mar-2026 Anklehwar Dahej Mohol
No. of Regulatory inspection 02 WHO (Local FDA) & WHO - CDSCO 4 (1 USFDA, 3 State FDA) 1 (State FDA)
No. of customer Audits 88 45 13
Total 90 49 14

IT Readiness

The following Independent IT systems have been implemented:

? SAP S/4HANA

? SAP Successfactors

? Open text for QMS Document (Master Production Control Record, Specification and Analytical Test data sheet)

? Trackwise for QMS (Out of specification investigation, Deviation Investigation and Change management system)

R&D

Our R&D teams focus on new products development, and complex molecules, cost improvement programs (CIP), process improvements and oncology product development, and novel polymorphism development.

To assist us with our R&D initiatives, we have established dedicated teams for:

? NEW PRODUCTS DEVELOPMENT

? ONCOLOGY PRODUCT DEVELOPMENT

? PRODUCT LIFE CYCLE MANAGEMENT

? COMPLEX PRODUCTS

? TECHNOLOGY TRANSFER

? PROJECT MANAGEMENT

? INTELLECTUAL PROPERTY MANAGEMENT

R&D is driving new growth levers through complex chemistry, flow chemistry, particle engineering and green chemistry.

We also adopt a thorough and systematic approach to product selection for our development grid, that considers factors such as a detailed commercial evaluation of the market opportunity of a particular API, its development complexity, intellectual property landscape, approved indications and the potential competitive scenario.

Our product and service line up together enable us to support our customers through all stages of the products lifecycle and be present across the value chain from product identification, R&D, impurity identification, methods development and controls, setting specifications and laboratory validation followed by technology transfer via pilot scale-up in the commercial plant.

This is followed by plant validation and product filing, enabling commercialization and large-scale manufacturing.

Our capabilities and experience have helped us perform well in regulated markets and have enabled us to successfully partner with customers, including offering our customers a first-mover advantage with respect to various products. We regularly work on developing eight to ten molecules each year which are field in multiple markets.

To lead the future, we have acquired land in Talaja (Navi Mumbai) admeasuring 10,000 square meter to establish a state-of-the-art R&D centre, designed to advance complex chemistry, analytical characterization and oncology research. The centre will focus on flow chemistry, complex products, particle engineering and green chemistry, thereby strengthening our pipeline across key therapeutic areas.

The new R&D centre for API will be equipped with capabilities for APIs, API+ platforms, pellets and CDMO services.

Building A Strong Product Portfolio

Our comprehensive approach while selecting products into our pipeline:

? Molecules value and volume growth across markets namely, US, EU, JP, ROW, India, LATAM

? Near-term prospects of the molecule in terms of patent expiration and novelty of the therapeutic area

? Capability to offer an edge in terms of speed, faster market entry and cost

? Special focus on NCE-1 opportunity for the US market

? Create high barriers by introducing novel and efficient routes that can be patented

Our portfolio comprises 176 products, (24 new products are under development pipeline including 1 iron complex and 9 HPAPIs), ranging across various chronic therapy areas like cardiovascular, CNS, diabetes, anti-infective, pain and others. The total addressable market size of Alivis products globally was estimated to be around US$ 267 billion by 2026 with a growth rate of about 11% over the horizon. The future growth of these products is expected to remain stable driven by the rising prevalence of chronic diseases, growing demand from the regulated markets for drugs indicated for hypertension, diabetes and cancer, and an ageing population.

(Chart: Total Addressable Market Size - Alivus Molecules: 116 (2019), 127 (9%) (2020), 138 (9%) (2021), 187 (35%) (2022), 197 (5%) (2023), 215 (10%) (2024), 240 (12%) (2025), 267 (11%) (2026))

The market size in terms of volume for Alivus APIs is estimated to be 14,880 MT by 2026 at a growth rate of 3%.

(Chart: Market Size - Alivus APIs Volume (MT): 5,391 (2019), 5,770 (7%) (2020), 6,098 (6%) (2021), 8,176 (34%) (2022), 8,599 (5%) (2023), 13,669 (59%) (2024), 14,395 (5%) (2025), 14,880 (3%) (2026))

Alivus portfolio of 176 niche, highly profitable and technically complex products cater to large chronic therapy areas such as CNS, diabetes, CVS (including anti-thrombotic) and oncology.

(Pie Chart: Therapy Count of product Total: 176 - Others 50, Oncology 20, Gastro 9, Diabetes 13, CVS 31, CNS 27, Anti-infective 12, Respiratory 7, Pain Management 7)

Performance and Operations Overview

(Charts: Total Income (INR Millions) FY25: 24,215, FY26: 26,122, YOY 7.9%; Gross Profit (INR Millions) FY25: 13,061, FY26: 14,853, YOY 13.7%; EBITDA (INR Millions) FY25: 7,172 (30.0%), FY26: 8,577 (33.6%), YOY 19.6%; Net Profit (INR Millions) FY25: 4,857 (20.3%), FY26: 5,645 (22.1%), YOY 16.2%; EPS (INR) FY25: 39.63, FY26: 45.99, YOY 16.1%)

Revenue From Operations

Alivus registered a Revenue from operations of INR 25,518 Mn for FY26, a growth of 6.9% YoY.

Total Income

Our total income increased by 7.9% to INR 26,122 million for the financial year 2026 from INR 24,215 million for the financial year 2025, primarily due to strong growth momentum across regulated markets. 6.9% INR 25,518 Mn 7.9% INR 26,122 Mn

Gross Profit

Gross Profit as a percentage to Revenues increased by 350 bps despite the absence of PLI benefit, which was availed until FY24.

Employee Benefits Expense

Employee benefits expenses increased by 8.3% to INR 2,725 million for the financial year 2026 from INR 2,517 million for the financial year 2025 due to annual increment and rise in headcount.

Other Expenses

Other expenses increased by 11.8% to INR 4,155 million for the financial year 2026 from INR 3,718 million for the financial year 2025, primarily due to an increase in repair and maintenance by 48.4% to INR 741 million for the financial year 2026 from INR 499 million for the financial year 2025, an increase in Freight outward by 22.1% to INR 239 million for the financial year 2026 from INR 195 million for the financial year 2025, an increase in Job work Charges by 25.5% to INR 242 million for the financial year 2026 from INR 193 million for the financial year 2025 and an increase in Insurance charges by 38.2% to INR 98 million for the financial year 2026 from INR 71 million for the financial year 2025. Increase in other expenses slightly offset by decrease in utility charges by 2.9% to INR 1139 million for the financial year 2026 from INR 1172 million for the financial year 2025.

R&D Expenditure

R&D expenditures were INR 925 million at 3.6% of sales for FY26. (FY25- INR 805 million at 3.4%) 14.9% INR 925 Mn

CAPEX Expenditures

Capital expenditures were INR 3,071 million for FY26. (FY25- INR 1,662 million)

Cash and Cash Equivalents

Cash and cash equivalents (including short term investments) were INR 7,824 million as on 31 March 2026. (31 March 2025 - INR 5,487 million)

Key Financials Ratios

Particulars 31 March 2026 31 March 2025 % Variance
Current Ratio 5.21 4.97 5.00%
Return on Equity (ROE) 18.36% 18.86% -2.66%
Inventory Turnover Ratio 1.56 1.61 -3.15%
Trade Receivables Turnover Ratio 2.50 2.75 -9.19%
Trade Payables Turnover Ratio 2.84 2.87 -0.92%
Net Capital Turnover Ratio 1.19 1.28 -6.89%
Net Profit Ratio 22.12% 20.35% 8.71%
Return on Capital Employed (ROCE) 22.52% 23.02% -2.17%
Return on Mutual Fund Investments 5.82% 2.01% 189.34%
FY2026 FY2025 FY2024
Generic 93% 94% 93%
CDMO 7% 6% 7%

Internal Controls

In line with the requirements under the SEBI LORD, the Company has constituted a Risk Management Committee of the Directors. The Members of the Committee are Mr. Kaushikbhai Patel (Chairman), Dr. Yasir Rawjee and Mr. T.L. Easwar.

The Committee met twice in FY26 to discuss and evaluate risks associated with the business and the mitigation plans for the same.

The Company has adequate internal controls systems in place which provides reasonable assurance about the integrity and reliability of financial statements. Additionally, Shridhar & Associates, a leading audit firm performs periodic internal audits to provide reasonable assurance over internal control effectiveness and advises on industry-wide best practices.

The Audit Committee consisting of Independent Directors review important issues raised by the Internal and Statutory Auditors, thereby ensuring that risks are mitigated appropriately with necessary rectification measures on a periodic basis.

Risk Management

Risk Mitigation Plan
Regulatory Risk An adverse facility inspection by any regulator may cause restriction in sales to certain customers or respective geographies We have established systems to always monitor compliance. Our employees receive training on compliance updates for always confirming to them
Supply Chain The failure of a small number of single-source, third-party suppliers or service providers to fulfil their contractual obligations in a timely manner or as a result of regulatory non-compliance or physical disruption at their manufacturing sites may result in delays or service interruptions, which may materially and adversely affect the Companys revenues Where practical, dependencies on single sources of critical items are removed by developing alternative sources. In rare cases where dual sourcing is not possible, an inventory strategy has been developed to protect the supply chain from unanticipated disruptions.
Market Risk Market risks are the possibilities of losses because of price fluctuations, competitive scenario, geopolitical events, foreign exchange fluctuations, worldwide pandemics, and other events can all have an impact on market movements The Company has initiated measures to reduce costs, improve efficiencies and reallocate resources to support identified growth opportunities in various markets. The Company is also continuously evaluating further strategic options to ensure the development of new capabilities and the ability to maximise the value of the Companys current and future portfolio. The Company makes conscious efforts to launch new value added products with some differentiation i.e. improvised products which can fetch better pricing. External uncertainties are carefully considered when developing strategy and reviewing performance. The Company has a board approved hedging policy in place to manage its currency risk exposure. External uncertainties are carefully considered when developing strategy and reviewing performance. The Company has a board approved hedging policy in place to manage its currency risk exposure.
Risks & its De nition Mitigation Plan
Compliance The Companys internal control framework is
The Companys operations subject it to designed to help ensure that we adhere to legal and
compliance with a broad range of laws and regulatory requirements through continuous
regulatory controls on the development, evaluation. We are in the process of further
manufacturing, testing, approval, distribution strengthening the framework to meet the evolving
and marketing of its pharmaceutical products and regulations. We have implemented a compliance
affect not only the cost of product development management tool which shall enable the management
but also the time required to reach the market to monitor compliance at various levels.
and the uncertainty of successfully doing so.
The Board also evaluates the compliance framework
Additionally, the Company is also subjected to
of the Company on a periodic basis.
regulations with respect to listing of its shares on
stock exchanges, nancial reporting, and tax.
Environment, Health & Safety The Company operates rigorous procedures to seek
The environment laws of various jurisdictions to eliminate hazards where practicable and protect
impose actual and potential obligations on the employees health and well-being. It has also
Company to remediate contaminated sites. undertaken a safety c ulture transformation
programme in partnership with a renowned third-
Failure to manage the environment risks properly party partner to further strengthen its safety culture
could result in additional remedial costs that may and systems.
materially and adversely affect the Companys
nancial results. The Companys continuing efforts to improve
environmental sustainability have reduced the
Failure to adhere to Health & Safety standards Companys water consumption, hazardous waste,
can result in temporary or long term cessation of and energy consumption. The Company actively
activities at our manufacturing plants. manages our environmental remediation obligations
to ensure practices are environmentally sustainable
and compliant.
Additionally, a separate ESG Board Committee has
been formed to regularly monitor developments and
progress of the Company on various initiatives taken
by the Company on the ESG front.
Information Technology & Cyber Security Risk The Company fosters a risk-aware culture that can
For its operations, the Company is heavily reliant anticipate and prevent attacks, and where necessary,
on IT systems. effectively respond to security breaches, maintain
strong cybersecurity infrastructure and compliance
A failure of IT systems due to malicious attacks with data privacy law requirements through:
and/or non-compliance with data privacy laws
can potentially lead to nancial loss, business Performing gap analysis to identify existing
disruption and/or damage to our reputation. weaknesses
Policy and procedure rollouts
Creating awareness amongst employees on
applicable privacy requirements
Securing suitable insurance cover

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.